GβL Inhibitors
GβL inhibitors are a class of chemical compounds designed to target and modulate the function of the GβL (G protein beta-like) protein, a critical component of the mTOR (mechanistic target of rapamycin) complex. GβL, also known as LST8, is an evolutionarily conserved protein that forms part of both the mTORC1 and mTORC2 complexes. Its role is to stabilize and support the catalytic activity of mTOR, influencing the regulation of cellular growth, nutrient sensing, and metabolic homeostasis. By inhibiting GβL, these compounds may disrupt its interactions within the mTOR complexes, thereby modulating the function of mTOR itself. This inhibition can provide valuable insight into the dynamics of protein complex formation and its downstream biochemical signaling pathways.
GβL inhibitors may be designed to interfere with the binding of GβL to mTOR or other associated proteins within the complex, such as Raptor in mTORC1 or Rictor in mTORC2. These inhibitors could function by directly binding to the GβL protein, causing conformational changes that prevent its incorporation into the complex, or by blocking key interaction sites that are necessary for its stabilizing function. The design of these inhibitors would involve techniques such as structure-based drug design, utilizing data from crystallographic or cryo-electron microscopy studies to identify critical binding regions. High-throughput screening methods and structure-activity relationship (SAR) studies could further refine the specificity and potency of these compounds. By inhibiting GβL, researchers can explore the broader biological roles of the mTOR complexes and how GβL contributes to cellular processes like nutrient sensing and growth regulation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
As an mTORC1 inhibitor, rapamycin may indirectly lead to the downregulation of GβL by disrupting upstream signaling pathways that converge on mTORC2, of which GβL is a crucial component. This disruption could result in a compensatory decrease in GβL synthesis or stability. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY 294002 targets PI3K, which is upstream of AKT and mTORC2; inhibition of this kinase is likely to result in a decrease in the synthesis of GβL by reducing the activation state of mTORC2, as GβL expression is tightly linked to mTORC2 activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin, another PI3K inhibitor, would similarly decrease GβL expression by reducing AKT phosphorylation and activation, leading to diminished mTORC2 function and potentially less GβL protein synthesis as part of the mTORC2 complex's regulatory feedback loop. | ||||||
PP242 | 1092351-67-1 | sc-301606A sc-301606 | 1 mg 5 mg | $56.00 $169.00 | 8 | |
PP242 directly targets both mTOR complexes. It would reduce GβL expression by inhibiting the kinase activity of mTOR within mTORC2, thereby destabilizing the complex and lowering the expression levels of its components, including GβL. | ||||||
Torin 1 | 1222998-36-8 | sc-396760 | 10 mg | $240.00 | 7 | |
Torin 1, by inhibiting both mTORC1 and mTORC2, would directly decrease GβL expression. This compound would hinder the assembly and reduce the activity of mTORC2, leading to a downregulation of GβL, which is essential for mTORC2's structural and functional integrity. | ||||||
KU 0063794 | 938440-64-3 | sc-361219 | 10 mg | $209.00 | ||
Through its inhibition of mTOR's kinase activity,KU 0063794 would decrease GβL expression by directly disrupting mTORC2, where GβL is a key structural element. The resulting destabilization of mTORC2 would lead to reduced expression levels of GβL. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $60.00 $185.00 $365.00 | 64 | |
Resveratrol could indirectly lead to a reduction in GβL expression by activating sirtuins and AMPK, which may downregulate mTORC1 signaling. This could initiate a cascade effect, resulting in a decrease in GβL expression as part of the mTORC2 complex due to the tight regulation between these two complexes. | ||||||
Quercetin | 117-39-5 | sc-206089 sc-206089A sc-206089E sc-206089C sc-206089D sc-206089B | 100 mg 500 mg 100 g 250 g 1 kg 25 g | $11.00 $17.00 $108.00 $245.00 $918.00 $49.00 | 33 | |
Quercetin, by inhibiting PI3K/AKT signaling, would lead to a decrease in mTORC2 activity. Given that GβL is integral to mTORC2, this suppression would likely result in a downregulation of GβL expression, reflecting the complex's reduced functional state. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $36.00 $68.00 $107.00 $214.00 $234.00 $862.00 $1968.00 | 47 | |
Curcumin has been found to downregulate the mTOR pathway, which could lead to a consequent decrease in GβL expression. The reduction in mTOR activity, due to curcumin's action, might suppress the synthesis of mTOR complex components, including GβL. | ||||||
Metformin | 657-24-9 | sc-507370 | 10 mg | $77.00 | 2 | |
Metformin activates AMPK, which in turn inhibits mTORC1 signaling. This inhibition can cause a ripple effect, potentially leading to a decrease in GβL expression as part of a feedback mechanism affecting mTORC2, despite GβL being more directly associated with the latter. | ||||||